V.F.Snegirev Archives of Obstetrics and GynecologyV.F.Snegirev Archives of Obstetrics and Gynecology2313-87262687-1386Eco-Vector10909610.17816/2313-8726-2022-9-2-73-81Review ArticleThe stimulation of ovulation and endometrial carcinogenesis: possible relationship and study prospects (literature review)KlyukinaLidiya A.<p>post-graduate student</p>lidiaklyukina@mail.ruhttps://orcid.org/0000-0001-7602-4584SosnovaElena A.<p>M.D., Dr. Sci. (Med.), Professor</p>sosnova-elena@inbox.ruhttps://orcid.org/0000-0002-1732-6870IshchenkoAnton A.<p>MD, PhD, Head of the Center for Gynecology and New Reproductive Technologies</p>ra2001_2001@mail.ruhttps://orcid.org/0000-0002-4476-4972I.M. Sechenov First Moscow State Medical UniversityMedical and Rehabilitation Center300620229273813006202230062022Copyright © 2022, Klyukina L.A., Sosnova E.A., Ishchenko A.A.2022<p>Currently, infertility is still a global problem; therefore, reproductive doctors worldwide are actively studying new and improving existing methods of overcoming female infertility. In recent years, the arsenal of drugs that can stimulate ovarian function has significantly expanded. A prerequisite for the use of drugs in this group is the presence of a follicular apparatus in the ovaries. Ovulation inducers contribute to the maturation of several follicles at once, and their ability to influence the process of steroidogenesis is beyond doubt. However, the long-term risk assessment when using these drugs, namely the risk of developing malignant female reproductive system neoplasm, remains poorly understood despite their long-term use. This problem is multifaceted and quite difficult to study since the etiological causes of infertility are considered a risk factor for developing malignant female reproductive system neoplasms. Oncological diseases are diagnosed several years after infertility treatment, thus proving a causal relationship is difficult, on the one hand, and dictating the need for a long period of observation in the group of women who underwent infertility treatment, considering the characteristics of each specific method, on the other hand. Herein, the authors analyzed the results of published studies on the possible relationship between ovulation induction and the risk of developing cancer in the uterine body.</p>stimulation of ovulationendometrial cancerclomiphene citrateassisted reproductive technologiesreviewстимуляция овуляциирак эндометриякломифен цитратвспомогательные репродуктивные технологииобзор[Cetin I, Cozzi V, Antonazzo P, et al. Infertility as a cancer risk factor ― a review. Placenta. 2008;29 Suppl. B:169–177. doi: 10.1016/j.placenta.2008.08.007][Sunderam S, Kissin DM, Crawford SB, et al. Assisted reproductive technology surveillance ― United States, 2011. MMWR Surveill Summ. 2014;63(10):1–28.][Jensen A, Sharif H, Olsen JH, Kruger Kjaer S. Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. Am J Epidemiol. 2008;168(1):49–57. doi: 10.1093/aje/kwn094][Giudice LC. Endometrium in PCOS: implantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab. 2006;20(2):235–244. doi: 10.1016/j.beem.2006.03.005][Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003;361:1810–1812. doi: 10.1016/s0140-6736(03)13409-5][Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456–488. doi: 10.1016/j.fertnstert.2008.06.035][Mikhailova ND, Mishieva NG, Kirillova AO, Dzhincharadze LG. Modern methods of infertility treatment in patients with polycystic ovary syndrome. Obstetrics and Gynecology. 2021;(7):37–44. (In Russ). doi: 10.18565/aig.2021.7.37-44][Carmina E, Guastella E, Longo RA. Advances in the Diagnosis and Treatment of PCOS. Curr Pharm Des. 2016;22(36):5508–5514. doi: 10.2174/1381612822666160719105808][Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–47. doi: 10.1093/humrep/deh098][El Hayek S, Bitar L, Hamdar LH, Mirza FG, Daoud G. Polycystic ovarian syndrome: an updated overview. Front Physiol. 2016;7:124. doi: 10.3389/fphys.2016.00124][Livadas S, Pappas C, Karachalios A, et al. Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome. Endocrine. 2014;47(2):631–638. doi: 10.1007/s12020-014-0200-7][Cattrall FR, Healy DL. Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18(5):803–812. doi: 10.1016/j.bpobgyn.2004.05.005][Barrett-Lee PJ. Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy. Endocr Relat Cancer. 2005;12 Suppl. 1:S125–133. doi: 10.1677/erc.1.01024][Tokmak A, Kokanali MK, Guzel AI, et al. Polycystic Ovary Syndrome and Risk of Endometrial Cancer: a Mini-Review. Asian Pac J Cancer Prev. 2014;15(17):7011–7014. doi: 10.7314/apjcp.2014.15.17.7011][Subramaniam KS, Tham ST, Mohamed Z, et al. Cancer-associated fibroblasts promote proliferation of endometrial cancer cells. PLoS One. 2013;8(7):e68923. doi: 10.1371/journal.pone.0068923][Apparao KB, Lovely LP, Gui Y, Lininger RA, Lessey BA. Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biol Reprod. 2002;66(2):297–304. doi: 10.1095/biolreprod66.2.297][Villavicencio A, Bacallao K, Avellaira C, et al. Androgen and estrogen receptors and co-regulators levels in endometria from patients with polycystic ovarian syndrome with and without endometrial hyperplasia. Gynecol Oncol. 2006;103(1):307–314. doi: 10.1016/j.ygyno.2006.03.029][MacLaughlan SD, Palomino WA, Mo B, et al. Endometrial expression of Cyr61: a marker of estrogenic activity in normal and abnormal endometrium. Obstet Gynecol. 2007;110(1):146–154. doi: 10.1097/01.AOG.0000269047.46078.28][Chien W, Kumagai T, Miller CW, et al. Cyr61 suppresses growth of human endometrial cancer cells. J Biol Chem. 2004;279(51):53087–53096. doi: 10.1074/jbc.M410254200][Pillay OC, Te Fong LF, Crow JC, et al. The association between polycystic ovaries and endometrial cancer. Hum Reprod. 2006;21(4):924–929. doi: 10.1093/humrep/dei420][Villavicencio A, Bacallao K, Gabler F, et al. Deregulation of tissue homeostasis in endometria from patients with polycystic ovarian syndrome with and without endometrial hyperplasia. Gynecol Oncol. 2007;104(2):290–295. doi: 10.1016/j.ygyno.2006.09.003][Dos Santos Silva I., Wark PA, McCormack VA, et al. Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohort. Br J Cancer. 2009;100(11):1824–1831. doi: 10.1038/sj.bjc.6605086][Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28–38. e25. doi: 10.1016/j.fertnstert.2011.09.024][Benshushan A, Paltiel O, Brzezinski A, et al. Ovulation induction and risk of endometrial cancer: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2001;98(1):53–57. doi: 10.1016/s0301-2115(01)00344-x][Brinton LA, Westhoff CL, Scoccia B, et al. Causes of infertility as predictors of subsequent cancer risk. Epidemiology. 2005;16(4):500–507. doi: 10.1097/01.ede.0000164812.02181.d5][Luke B, Brown MB, Spector LG, et al. Cancer in women after assisted reproductive technology. Fertil Steril. 2015;104(5):1218–1226. doi: 10.1016/j.fertnstert.2015.07.113][Hanson B, Johnstone E, Dorais J, et al. Female infertility, infertility-associated diagnoses, and comorbidities: a review. J Assist Reprod Genet. 2017;34(2):167–177. doi: 10.1007/s10815-016-0836-8][Venn A, Jones P, Quinn M, Healy D. Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecol Oncol. 2001;82(1):64–68. doi: 10.1006/gyno.2001.6209][Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod. 2002;17(8):2209–2213. doi: 10.1093/humrep/17.8.2209][Dor J, Lerner-Geva L, Rabinovici J, et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril. 2002;77(2):324–327. doi: 10.1016/s0015-0282(01)02986-7][Althuis MD, Moghissi KS, Westhoff CL, et al. Uterine cancer after use of clomiphene citrate to induce ovulation. Am J Epidemiol. 2005;161(7):607–615. doi: 10.1093/aje/kwi084][Calderon-Margalit R, Friedlander Y, Yanetz R, et al. Cancer risk after exposure to treatments for ovulation induction. Am J Epidemiol. 2009;169(3):365–375. doi: 10.1093/aje/kwn318][Jensen A, Sharif H, Kjaer SK. Use of fertility drugs and risk of uterine cancer: results from a large Danish population-based cohort study. Am J Epidemiol. 2009;170(11):1408–1414. doi: 10.1093/aje/kwp290][Parazzini F, Pelucchi C, Talamini R, Montella M, La Vecchia C. Use of fertility drugs and risk of endometrial cancer in an Italian case–control study. Eur J Cancer Prev. 2010;19(6):428–430. doi: 10.1097/CEJ.0b013e32833d9388][Lerner-Geva L, Rabinovici J, Olmer L, et al. Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow-up. Gynecol Endocrinol. 2012;28(10):809–814. doi: 10.3109/09513590.2012.671391][Kessous R, Davidson E, Meirovitz M, Sergienko R, Sheiner E. The risk of female malignancies after fertility treatments: a cohort study with 25-year follow-up. J Cancer Res Clin Oncol. 2016;142(1):287–293. doi: 10.1007/s00432-015-2035-x][Reigstad MM, Storeng R, Myklebust TÅ, et al. Cancer risk in women treated with fertility drugs according to parity status — a registry-based cohort study. Cancer Epidemiol Biomarkers Prev. 2017;26(6):953–962. doi: 10.1158/1055-9965.EPI-16-0809][Williams CL, Jones ME, Swerdlow AJ, et al. Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991–2010: data linkage study including 2.2 million person years of observation. BMJ. 2018;362:k2644. doi: 10.1136/bmj.k2644]